Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Novartis fracture drug

The US Food and Drug Administration has approved Novartis' osteoporosis drug, Reclast, for use in patients suffering the crippling after-effects of hip fractures
The US Food and Drug Administration (FDA) has approved Novartis' osteoporosis drug, Reclast, for use in patients suffering the crippling after-effects of hip fractures.

Novartis says the drug is the only treatment currently available to prevent further bone injuries after low-trauma hip fractures, sustained after a fall from standing height or less.

Osteoporosis affects around 10 million people in the US and causes some 297,000 hip fractures. Of those people who suffer a hip fracture, 50 per cent will need help walking and 25 per cent will have to be given long-term nursing care. All patients are at risk of further breaks and almost a quarter of them over the age 50 die within a year.

Professor Kenneth Saag, from the division of clinical immunology and rheumatology at the University of Alabama, explained that few patients are in receipt of hip fracture aftercare to prevent further complications.

Reclast was tested during the Recurrent Fracture Trial, which involved 2,100 female and male patients over 50 with the condition who had sustained a hip fracture. Results from the study showed that the drug increased bone mineral density (BMD) and reduced the risk of secondary injuries by 35 per cent.

"The consequences of osteoporosis can be devastating, particularly hip fractures," said Saag. "In the first large-scale clinical trial of its kind, these data support an efficacious therapeutic option for patients after a hip fracture."

The FDA made the decision to approve the drug for use based on data from the trial, which has now been published in The New England Journal of Medicine. Reclast is already approved in the US and the EU, where it is marketed under the name Aclasta, for the treatment of postmenopausal osteoporosis.

The FDA decision will see the drug's label updated to include information for the new indication.

5th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics